We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mead Johnson-Reckitt Move to Merge, Deal Closes on Jun 15
Read MoreHide Full Article
Mead Johnson Nutrition Company , the Enfamil infant formula-maker is fast moving toward concluding the agreement of acquisition with renowned British consumer-products maker, Reckitt Benckiser Group. Post clearance of the final regulatory hurdle, the company announced Jun15 as the closing date for this mega $16.7 billion deal.
This news follows Mead Johnson’s announcement that both companies’ stockholders have approved the impending merger earlier this month.
The total transaction value of the deal had previously been fixed at $17.9 billion including Mead Johnson’s net debt of $1.2 billion as of Dec 31, 2016. This represents $90 per share of company’s common stock which is equivalent to 29% premium to its closing share price on Feb 1, before market speculation of a potential contract was rife.
Reckitt Benckiser incidentally plans to add Mead Johnson’s global brands Enfamil and Nutramigen as a new division within the company’s portfolio.
Both companies expect the deal to be strategic fit. Successful completion of this integration will lead to medium to long-term growth of 3–5% in global infant and children’s nutrition category of Mead Johnson, which is currently worth approximately $46 billion in annual sales.
After an initial transitional period, Reckitt Benckiser expects to perform progressively toward achieving the upper end of this estimated range.
Reckitt Benckiser’s multi-geography supply chain infrastructure and distribution network should enhance Mead Johnson’s go-to-market capabilities. This apart, it would accelerate Mead Johnson’s entry into new emerging geographies where Reckitt Benckiser already has a deep and existing understanding of the local consumer health dynamics.
From financial perspective, the consolidation is expected to be accretive to adjusted earnings per share of Reckitt Benckiser in first full-year and double-digit accretive by the third year. Additionally, there will be 200 million pounds of annual cost savings.
Zacks Rank & Key Picks
With limited upside potential, Mead Johnson currently carries a Zacks Rank #4 (Sell). Few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 37.9% over last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 84.7%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has roughly added 15.9% over last three months.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
Mead Johnson-Reckitt Move to Merge, Deal Closes on Jun 15
Mead Johnson Nutrition Company , the Enfamil infant formula-maker is fast moving toward concluding the agreement of acquisition with renowned British consumer-products maker, Reckitt Benckiser Group. Post clearance of the final regulatory hurdle, the company announced Jun15 as the closing date for this mega $16.7 billion deal.
This news follows Mead Johnson’s announcement that both companies’ stockholders have approved the impending merger earlier this month.
The total transaction value of the deal had previously been fixed at $17.9 billion including Mead Johnson’s net debt of $1.2 billion as of Dec 31, 2016. This represents $90 per share of company’s common stock which is equivalent to 29% premium to its closing share price on Feb 1, before market speculation of a potential contract was rife.
Mead Johnson Nutrition Company Price
Mead Johnson Nutrition Company Price | Mead Johnson Nutrition Company Quote
Reckitt Benckiser incidentally plans to add Mead Johnson’s global brands Enfamil and Nutramigen as a new division within the company’s portfolio.
Both companies expect the deal to be strategic fit. Successful completion of this integration will lead to medium to long-term growth of 3–5% in global infant and children’s nutrition category of Mead Johnson, which is currently worth approximately $46 billion in annual sales.
After an initial transitional period, Reckitt Benckiser expects to perform progressively toward achieving the upper end of this estimated range.
Reckitt Benckiser’s multi-geography supply chain infrastructure and distribution network should enhance Mead Johnson’s go-to-market capabilities. This apart, it would accelerate Mead Johnson’s entry into new emerging geographies where Reckitt Benckiser already has a deep and existing understanding of the local consumer health dynamics.
From financial perspective, the consolidation is expected to be accretive to adjusted earnings per share of Reckitt Benckiser in first full-year and double-digit accretive by the third year. Additionally, there will be 200 million pounds of annual cost savings.
Zacks Rank & Key Picks
With limited upside potential, Mead Johnson currently carries a Zacks Rank #4 (Sell). Few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 37.9% over last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 84.7%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has roughly added 15.9% over last three months.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>